RECURSION PHARMACEUTICALS (RXRX) JUMPS 9.6% AHEAD OF Q2 EARNINGS
https://s.yimg.com/ny/api/res/1.2/kw15oVFT8Nw9PKshleui.Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/198a1516872a8cd09220c99d73a2f530
✍️ Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of Monday's biggest gainers, adding 9.59% to close at $6.40 apiece ahead of its second quarter earnings results.
👉 Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of Monday's biggest gainers, adding 9.59% to close at $6.40 apiece. 👉 Company's senior director, Peter Ray, posted about an ongoing drug candidate, REC-3565. 👉 REC-3565 aims to treat relapsed or refractory B-cell lymphomas. 👉 Drug candidate is being developed using the company's advanced AI platform. 👉 AI platform is not conceived through traditional human design methods.
-- #PeterRay #business
Loading quoted post…
